6lur

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
==Human PUF60 UHM domain (thioredoxin fusion) in complex with a small molecule binder==
==Human PUF60 UHM domain (thioredoxin fusion) in complex with a small molecule binder==
-
<StructureSection load='6lur' size='340' side='right'caption='[[6lur]]' scene=''>
+
<StructureSection load='6lur' size='340' side='right'caption='[[6lur]], [[Resolution|resolution]] 2.00&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6LUR OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6LUR FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[6lur]] is a 8 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6LUR OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6LUR FirstGlance]. <br>
-
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6lur FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6lur OCA], [http://pdbe.org/6lur PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6lur RCSB], [http://www.ebi.ac.uk/pdbsum/6lur PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6lur ProSAT]</span></td></tr>
+
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EVU:4-[2-[4-(aminomethyl)phenyl]phenyl]piperazin-2-one'>EVU</scene></td></tr>
 +
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">PUF60, FIR, ROBPI, SIAHBP1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6lur FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6lur OCA], [http://pdbe.org/6lur PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6lur RCSB], [http://www.ebi.ac.uk/pdbsum/6lur PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6lur ProSAT]</span></td></tr>
</table>
</table>
 +
== Function ==
 +
[[http://www.uniprot.org/uniprot/THIO_ECOLI THIO_ECOLI]] Participates in various redox reactions through the reversible oxidation of its active center dithiol to a disulfide and catalyzes dithiol-disulfide exchange reactions.
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Recently, there has been increasing interest in new modalities such as therapeutic antibodies and gene therapy at a number of pharmaceutical companies. Moreover, in small-molecule drug discovery at such companies, efforts have focused on hard-to-drug targets such as inhibiting protein-protein interactions. Biomolecular NMR spectroscopy has been used in drug discovery in a variety of ways, such as for the reliable detection of binding and providing three-dimensional structural information for structure-based drug design. The advantages of using NMR spectroscopy have been known for decades (Jahnke in J Biomol NMR 39:87-90, (2007); Gossert and Jahnke in Prog Nucl Magn Reson Spectrosc 97:82-125, (2016)). For tackling hard-to-drug targets and increasing the success in discovering drug molecules, in-depth analysis of drug-target protein interactions performed by biophysical methods will be more and more essential. Here, we review the advantages of NMR spectroscopy as a key technology of biophysical methods and also discuss issues such as using cutting-edge NMR spectrometers and increasing the demand of utilizing conformational dynamics information for promoting small-molecule drug discovery.
 +
 +
Revisiting biomolecular NMR spectroscopy for promoting small-molecule drug discovery.,Hanzawa H, Shimada T, Takahashi M, Takahashi H J Biomol NMR. 2020 Apr 18. pii: 10.1007/s10858-020-00314-0. doi:, 10.1007/s10858-020-00314-0. PMID:32306215<ref>PMID:32306215</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 6lur" style="background-color:#fffaf0;"></div>
 +
== References ==
 +
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
 +
[[Category: Human]]
[[Category: Large Structures]]
[[Category: Large Structures]]
-
[[Category: Hanzawa H]]
+
[[Category: Hanzawa, H]]
-
[[Category: Takahashi M]]
+
[[Category: Takahashi, M]]
 +
[[Category: Splicing]]
 +
[[Category: Splicing factor]]

Revision as of 06:27, 6 May 2020

Human PUF60 UHM domain (thioredoxin fusion) in complex with a small molecule binder

PDB ID 6lur

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools